Guideline-recommended application of glucocorticoid in neurological disorders_West China Medical Journal

Authors：

LIU Meng ,  WU Simiao

Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

WU Simiao, Email: simiao.wu@hotmail.com

Keywords：

Glucocorticoids; neurological disorders; standardized clinical application; guidelines

DOI：

10.7507/1002-0179.202205015

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Glucocorticoids are the first-line therapy of many neurological disorders, with the treatment regimen varying across types and characteristics of neurological disorders. This article reviews the national and international guidelines and expert consensuses in the past decade on glucocorticoids treatment for neurological disorders, and summarizes recommendations from the latest Chinese guidelines and consensuses. In summary, the most frequently used pulse therapy of glucocorticoids in China is intravenous infusion of high-dose (usually 1000 mg/d) methylprednisolone in a short period (often <5 d), followed by gradual tapering, bridging with oral prednisone or direct discontinuation. The treatment regimen for children and juveniles is similar to that for adults but the dose is adjusted by body weight. Pharmacodynamics of glucocorticoids should be considered for the treatment of perinatal women. To provide appropriate glucocorticoids treatment for patients with neurological disorders, clinicians should fully understand features of each neurological disorder and clinical characteristics of individual patient.

Citation： LIU Meng, WU Simiao. Guideline-recommended application of glucocorticoid in neurological disorders. West China Medical Journal, 2022, 37(12): 1891-1898. doi: 10.7507/1002-0179.202205015 Copy

1.	Vandewalle J, Luypaert A, De Bosscher K, et al. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab, 2018, 29(1): 42-54.
2.	Galati A, Brown ES, Bove R, et al. Glucocorticoids for therapeutic immunosuppression: clinical pearls for the practicing neurologist. J Neurol Sci, 2021, 430: 120004.
3.	陳嘉欣, 馮慧宇. 重視常見神經免疫疾病激素沖擊治療和減量方案的規范性. 中華神經科雜志, 2021, 54(9): 876-884.
4.	寧光. 糖皮質激素類藥物臨床應用指導原則. 中華內分泌代謝雜志, 2012, 28(2): 171-202.
5.	Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ, 2021, 374: n1380.
6.	Nicolaides NC, Pavlaki AN, Maria Alexandra MA, et al. glucocorticoid therapy and adrenal suppression//Feingold KR, Anawalt B, Boyce A, et al. Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc., 2000.
7.	Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol, 1999, 58(2): 363-368.
8.	Buttgereit F, da Silva JAP, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002, 61(8): 718-722.
9.	Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15(4): 391-404.
10.	中華醫學會神經病學分會. 中國自身免疫性腦炎診治專家共識. 中華神經科雜志, 2017, 50(2): 91-98.
11.	Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci, 2019, 40(10): 2017-2030.
12.	Nosadini M, Thomas T, Eyre M, et al. International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis. Neurol Neuroimmunol Neuroinflamm, 2021, 8(5): e1052.
13.	McCarthy A, Dineen J, McKenna P, et al. Anti-NMDA receptor encephalitis with associated catatonia during pregnancy. J Neurol, 2012, 259(12): 2632-2635.
14.	中國免疫學會神經免疫分會, 中華醫學會神經病學分會神經免疫學組. 多發性硬化診斷和治療中國專家共識(2018 版). 中國神經免疫學和神經病學雜志, 2018, 25(6): 387-394.
15.	Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev, 2000(4): CD001331.
16.	Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord, 2020, 37: 101459.
17.	Laplaud D, Bodiguel E, Bensa C, et al. Recommendations for the management of multiple sclerosis relapses. Rev Neurol (Paris), 2012, 168(5): 425-433.
18.	Marques VD, Passos G, Mendes MF, et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq Neuropsiquiatr, 2018, 76(8): 539-554.
19.	Shatila AR, Koussa S, Jabbour R, et al. LSN MS guidelines for the management of multiple sclerosis. Rev Neurol (Paris), 2013, 169(12): 950-955.
20.	Huppke P, G?rtner J. A practical guide to pediatric multiple sclerosis. Neuropediatrics, 2010, 41(4): 157-162.
21.	Ghezzi A, Banwell B, Boyko A, et al. The management of multiple sclerosis in children: a European view. Mult Scler, 2010, 16(10): 1258-1267.
22.	Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol, 2011, 26(6): 675-682.
23.	Liguori NF, Alonso R, Pinheiro AA, et al. Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina. Mult Scler Relat Disord, 2020, 43: 102147.
24.	Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol, 2019, 19(2): 106-114.
25.	中國免疫學會神經免疫分會. 中國視神經脊髓炎譜系疾病診斷與治療指南(2021 版). 中國神經免疫學和神經病學雜志, 2021, 28(6): 423-436.
26.	Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord, 2020, 45: 102428.
27.	Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol, 2010, 17(8): 1019-1032.
28.	Sahraian MA, Moghadasi AN, Azimi AR, et al. Diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD) in Iran: a consensus guideline and recommendations. Mult Scler Relat Disord, 2017, 18: 144-151.
29.	Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol, 2014, 261(1): 1-16.
30.	Yamasaki R, Matsushita T, Fukazawa T, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler, 2016, 22(10): 1337-1348.
31.	中國免疫學會神經免疫分會. 抗髓鞘少突膠質細胞糖蛋白免疫球蛋白 G 抗體相關疾病診斷和治療中國專家共識. 中國神經免疫學和神經病學雜志, 2020, 27(2): 86-95.
32.	Bruijstens AL, Wendel EM, Lechner C, et al. E. U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders . Eur J Paediatr Neurol, 2020, 29: 41-53.
33.	賈建平, 陳生弟. 神經病學. 北京: 人民衛生出版社, 2015: 324.
34.	Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2011, 77(24): 2128-2134.
35.	中華醫學會神經病學分會, 中華醫學會神經病學分會周圍神經病協作組, 中華醫學會神經病學分會肌電圖與臨床神經電生理學組, 等. 中國慢性炎性脫髓鞘性多發性神經根神經病診治指南 2019. 中華神經科雜志, 2019, 52(11): 883-888.
36.	van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst, 2021, 26(3): 242-268.
37.	中華醫學會神經病學分會, 中華醫學會神經病學分會周圍神經病協作組, 中華醫學會神經病學分會肌電圖與臨床神經電生理學組, 等. 中國吉蘭-巴雷綜合征診治指南 2019. 中華神經科雜志, 2019, 52(11): 877-882.
38.	Leonhard SE, Mandarakas MR, Gondim F, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol, 2019, 15(11): 671-683.
39.	Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet, 2016, 388(10045): 717-727.
40.	Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Eur J Paediatr Neurol, 2020, 25: 5-16.
41.	中華醫學會神經病學分會, 中華醫學會神經病學分會神經肌肉病學組, 中華醫學會神經病學分會肌電圖與臨床神經電生理學組. 中國特發性面神經麻痹診治指南. 中華神經科雜志, 2016(2): 84-86.
42.	Fieux M, Franco-Vidal V, Devic P, et al. French Society of ENT (SFORL) guidelines. Management of acute Bell’s palsy. Eur Ann Otorhinolaryngol Head Neck Dis, 2020, 137(6): 483-488.
43.	De Almeida JR, Guyatt GH, Sud S, et al. Management of Bell palsy: clinical practice guideline. CMAJ, 2014, 186(12): 917-922.
44.	Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell’s palsy executive summary. Otolaryngol Head Neck Surg, 2013, 149(5): 656-663.
45.	Gronseth GS, Paduga R, American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2012, 79(22): 2209-2213.
46.	中華醫學會神經病學分會神經免疫學組, 中國免疫學會神經免疫學分會. 中國重癥肌無力診斷和治療指南 2015. 中華神經科雜志, 2015, 48(11): 934-940.
47.	中國免疫學會神經免疫分會. 中國重癥肌無力診斷和治療指南(2020 版). 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12.
48.	Nafissi S, Okhovat AA, Sinaei F, et al. Iranian consensus recommendations for treatment of myasthenia gravis. Arch Iran Med, 2022, 25(1): 37-49.
49.	Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci, 2019, 40(6): 1111-1124.
50.	Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 2016, 87(4): 419-425.
51.	Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol, 2015, 15(3): 199-206.
52.	Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol, 2010, 17(7): 893-902.
53.	Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol, 2016, 263(8): 1473-1494.
54.	Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 2021, 96(3): 114-122.
55.	Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol, 2014, 21(5): 687-693.
56.	Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol, 2015, 6(1): 21-31.
57.	Kadota Y, Horio H, Mori T, et al. Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014. Gen Thorac Cardiovasc Surg, 2015, 63(4): 201-215.
58.	Munot P, Robb SA, Niks EH, et al. 242nd ENMC International Workshop: diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscul Disord, 2020, 30(3): 254-264.
59.	中華醫學會神經病學分會, 中華醫學會神經病學分會神經肌肉病學組, 中華醫學會神經病學分會肌電圖及臨床神經生理學組. 中國多發性肌炎診治共識. 中華神經科雜志, 2015, 48(11): 946-949.
60.	Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol, 2019, 29(1): 1-19.
61.	中華醫學會神經病學分會, 中華醫學會神經病學分會神經肌肉病學組, 中華醫學會神經病學分會肌電圖與臨床神經生理學組. 中國假肥大型肌營養不良癥診治指南. 中華神經科雜志, 2016, 49(1): 17-20.
62.	中華醫學會醫學遺傳學分會遺傳病臨床實踐指南撰寫組. 杜氏進行性肌營養不良的臨床實踐指南. 中華醫學遺傳學雜志, 2020, 37(3): 258-262.
63.	中國免疫學會神經免疫學分會, 中華醫學會神經病學分會神經免疫學組, 中國醫師協會神經內科醫師分會神經免疫專員委業會. 原發性中樞神經系統血管炎診斷和治療中國專家共識. 中國神經免疫學和神經病學雜志, 2017, 24(4): 229-239.
64.	Beuker C, Strunk D, Rawal R, et al. Primary angiitis of the CNS: a systematic review and meta-analysis. Neurol Neuroimmunol Neuroinflamm, 2021, 8(6): e1093.
65.	Beelen J, Benseler SM, Dropol A, et al. Strategies for treatment of childhood primary angiitis of the central nervous system. Neurol Neuroimmunol Neuroinflamm, 2019, 6(4): e567.
66.	Sandercock PA, Soane T. Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev, 2011(9): CD000064.
67.	吳思緲, 吳波, 郭富強, 等. 重癥腦梗死優化診治方案及流程建議草案. 華西醫學, 2019, 34(10): 1096-1108.
68.	Torbey MT, B?sel J, Rhoney DH, et al. Evidence-based guidelines for the management of large hemispheric infarction: a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine. Neurocrit Care, 2015, 22(1): 146-164.
69.	Wijdicks EFM, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45(4): 1222-1238.
70.	van der Worp HB, Hofmeijer J, Jüttler E, et al. European Stroke Organisation (ESO) guidelines on the management of space-occupying brain infarction. Eur Stroke J, 2021, 6(2): XC-CX.

1. Vandewalle J, Luypaert A, De Bosscher K, et al. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab, 2018, 29(1): 42-54.
2. Galati A, Brown ES, Bove R, et al. Glucocorticoids for therapeutic immunosuppression: clinical pearls for the practicing neurologist. J Neurol Sci, 2021, 430: 120004.
3. 陳嘉欣, 馮慧宇. 重視常見神經免疫疾病激素沖擊治療和減量方案的規范性. 中華神經科雜志, 2021, 54(9): 876-884.
4. 寧光. 糖皮質激素類藥物臨床應用指導原則. 中華內分泌代謝雜志, 2012, 28(2): 171-202.
5. Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ, 2021, 374: n1380.
6. Nicolaides NC, Pavlaki AN, Maria Alexandra MA, et al. glucocorticoid therapy and adrenal suppression//Feingold KR, Anawalt B, Boyce A, et al. Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc., 2000.
7. Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol, 1999, 58(2): 363-368.
8. Buttgereit F, da Silva JAP, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002, 61(8): 718-722.
9. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15(4): 391-404.
10. 中華醫學會神經病學分會. 中國自身免疫性腦炎診治專家共識. 中華神經科雜志, 2017, 50(2): 91-98.
11. Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci, 2019, 40(10): 2017-2030.
12. Nosadini M, Thomas T, Eyre M, et al. International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis. Neurol Neuroimmunol Neuroinflamm, 2021, 8(5): e1052.
13. McCarthy A, Dineen J, McKenna P, et al. Anti-NMDA receptor encephalitis with associated catatonia during pregnancy. J Neurol, 2012, 259(12): 2632-2635.
14. 中國免疫學會神經免疫分會, 中華醫學會神經病學分會神經免疫學組. 多發性硬化診斷和治療中國專家共識(2018 版). 中國神經免疫學和神經病學雜志, 2018, 25(6): 387-394.
15. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev, 2000(4): CD001331.
16. Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord, 2020, 37: 101459.
17. Laplaud D, Bodiguel E, Bensa C, et al. Recommendations for the management of multiple sclerosis relapses. Rev Neurol (Paris), 2012, 168(5): 425-433.
18. Marques VD, Passos G, Mendes MF, et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq Neuropsiquiatr, 2018, 76(8): 539-554.
19. Shatila AR, Koussa S, Jabbour R, et al. LSN MS guidelines for the management of multiple sclerosis. Rev Neurol (Paris), 2013, 169(12): 950-955.
20. Huppke P, G?rtner J. A practical guide to pediatric multiple sclerosis. Neuropediatrics, 2010, 41(4): 157-162.
21. Ghezzi A, Banwell B, Boyko A, et al. The management of multiple sclerosis in children: a European view. Mult Scler, 2010, 16(10): 1258-1267.
22. Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol, 2011, 26(6): 675-682.
23. Liguori NF, Alonso R, Pinheiro AA, et al. Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina. Mult Scler Relat Disord, 2020, 43: 102147.
24. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol, 2019, 19(2): 106-114.
25. 中國免疫學會神經免疫分會. 中國視神經脊髓炎譜系疾病診斷與治療指南(2021 版). 中國神經免疫學和神經病學雜志, 2021, 28(6): 423-436.
26. Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord, 2020, 45: 102428.
27. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol, 2010, 17(8): 1019-1032.
28. Sahraian MA, Moghadasi AN, Azimi AR, et al. Diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD) in Iran: a consensus guideline and recommendations. Mult Scler Relat Disord, 2017, 18: 144-151.
29. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol, 2014, 261(1): 1-16.
30. Yamasaki R, Matsushita T, Fukazawa T, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler, 2016, 22(10): 1337-1348.
31. 中國免疫學會神經免疫分會. 抗髓鞘少突膠質細胞糖蛋白免疫球蛋白 G 抗體相關疾病診斷和治療中國專家共識. 中國神經免疫學和神經病學雜志, 2020, 27(2): 86-95.
32. Bruijstens AL, Wendel EM, Lechner C, et al. E. U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders . Eur J Paediatr Neurol, 2020, 29: 41-53.
33. 賈建平, 陳生弟. 神經病學. 北京: 人民衛生出版社, 2015: 324.
34. Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2011, 77(24): 2128-2134.
35. 中華醫學會神經病學分會, 中華醫學會神經病學分會周圍神經病協作組, 中華醫學會神經病學分會肌電圖與臨床神經電生理學組, 等. 中國慢性炎性脫髓鞘性多發性神經根神經病診治指南 2019. 中華神經科雜志, 2019, 52(11): 883-888.
36. van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst, 2021, 26(3): 242-268.
37. 中華醫學會神經病學分會, 中華醫學會神經病學分會周圍神經病協作組, 中華醫學會神經病學分會肌電圖與臨床神經電生理學組, 等. 中國吉蘭-巴雷綜合征診治指南 2019. 中華神經科雜志, 2019, 52(11): 877-882.
38. Leonhard SE, Mandarakas MR, Gondim F, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol, 2019, 15(11): 671-683.
39. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet, 2016, 388(10045): 717-727.
40. Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Eur J Paediatr Neurol, 2020, 25: 5-16.
41. 中華醫學會神經病學分會, 中華醫學會神經病學分會神經肌肉病學組, 中華醫學會神經病學分會肌電圖與臨床神經電生理學組. 中國特發性面神經麻痹診治指南. 中華神經科雜志, 2016(2): 84-86.
42. Fieux M, Franco-Vidal V, Devic P, et al. French Society of ENT (SFORL) guidelines. Management of acute Bell’s palsy. Eur Ann Otorhinolaryngol Head Neck Dis, 2020, 137(6): 483-488.
43. De Almeida JR, Guyatt GH, Sud S, et al. Management of Bell palsy: clinical practice guideline. CMAJ, 2014, 186(12): 917-922.
44. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell’s palsy executive summary. Otolaryngol Head Neck Surg, 2013, 149(5): 656-663.
45. Gronseth GS, Paduga R, American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2012, 79(22): 2209-2213.
46. 中華醫學會神經病學分會神經免疫學組, 中國免疫學會神經免疫學分會. 中國重癥肌無力診斷和治療指南 2015. 中華神經科雜志, 2015, 48(11): 934-940.
47. 中國免疫學會神經免疫分會. 中國重癥肌無力診斷和治療指南(2020 版). 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12.
48. Nafissi S, Okhovat AA, Sinaei F, et al. Iranian consensus recommendations for treatment of myasthenia gravis. Arch Iran Med, 2022, 25(1): 37-49.
49. Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci, 2019, 40(6): 1111-1124.
50. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 2016, 87(4): 419-425.
51. Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol, 2015, 15(3): 199-206.
52. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol, 2010, 17(7): 893-902.
53. Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol, 2016, 263(8): 1473-1494.
54. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 2021, 96(3): 114-122.
55. Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol, 2014, 21(5): 687-693.
56. Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol, 2015, 6(1): 21-31.
57. Kadota Y, Horio H, Mori T, et al. Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014. Gen Thorac Cardiovasc Surg, 2015, 63(4): 201-215.
58. Munot P, Robb SA, Niks EH, et al. 242nd ENMC International Workshop: diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscul Disord, 2020, 30(3): 254-264.
59. 中華醫學會神經病學分會, 中華醫學會神經病學分會神經肌肉病學組, 中華醫學會神經病學分會肌電圖及臨床神經生理學組. 中國多發性肌炎診治共識. 中華神經科雜志, 2015, 48(11): 946-949.
60. Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol, 2019, 29(1): 1-19.
61. 中華醫學會神經病學分會, 中華醫學會神經病學分會神經肌肉病學組, 中華醫學會神經病學分會肌電圖與臨床神經生理學組. 中國假肥大型肌營養不良癥診治指南. 中華神經科雜志, 2016, 49(1): 17-20.
62. 中華醫學會醫學遺傳學分會遺傳病臨床實踐指南撰寫組. 杜氏進行性肌營養不良的臨床實踐指南. 中華醫學遺傳學雜志, 2020, 37(3): 258-262.
63. 中國免疫學會神經免疫學分會, 中華醫學會神經病學分會神經免疫學組, 中國醫師協會神經內科醫師分會神經免疫專員委業會. 原發性中樞神經系統血管炎診斷和治療中國專家共識. 中國神經免疫學和神經病學雜志, 2017, 24(4): 229-239.
64. Beuker C, Strunk D, Rawal R, et al. Primary angiitis of the CNS: a systematic review and meta-analysis. Neurol Neuroimmunol Neuroinflamm, 2021, 8(6): e1093.
65. Beelen J, Benseler SM, Dropol A, et al. Strategies for treatment of childhood primary angiitis of the central nervous system. Neurol Neuroimmunol Neuroinflamm, 2019, 6(4): e567.
66. Sandercock PA, Soane T. Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev, 2011(9): CD000064.
67. 吳思緲, 吳波, 郭富強, 等. 重癥腦梗死優化診治方案及流程建議草案. 華西醫學, 2019, 34(10): 1096-1108.
68. Torbey MT, B?sel J, Rhoney DH, et al. Evidence-based guidelines for the management of large hemispheric infarction: a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine. Neurocrit Care, 2015, 22(1): 146-164.
69. Wijdicks EFM, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45(4): 1222-1238.
70. van der Worp HB, Hofmeijer J, Jüttler E, et al. European Stroke Organisation (ESO) guidelines on the management of space-occupying brain infarction. Eur Stroke J, 2021, 6(2): XC-CX.

Previous Article
Research progress of diagnosis and prediction system of stroke based on artificial intelligence
Next Article
Research progress of cystic neutrophilic granulomatous mastitis

West China Medical Journal

Guideline-recommended application of glucocorticoid in neurological disorders

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content